Foundayo (Orforglipron) Launch Timeline 2026
Full timeline
- 2026-04-01DONE
FDA approval (chronic weight management)
FDA approved Foundayo (orforglipron) for chronic weight management on April 1, 2026. Fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program; first new molecular entity (NME) cleared under CNPV. Approval was accelerated relative to the original PDUFA date thanks to the CNPV-compressed review window.
- 2026-04-06DONE
LillyDirect (direct-to-patient) launch
Eli Lilly began shipping Foundayo via LillyDirect five days after FDA approval, made possible by ~$1.5 billion in pre-manufactured inventory accumulated during the CNPV review. Launch pricing: $149/month for the 0.8 mg lowest dose; up to $299/month for higher doses within the 45-day refill window; $349/month standard for 14.5 / 17.2 mg out of refill window.
- 2026-04-09DONE
CVS, Walgreens, Ro, retail + telehealth availability
Retail pharmacy availability (CVS, Walgreens, most major chains) and Ro telehealth launched 8 days after FDA approval. Retail cash-pay typically runs $200-$300/month for the lowest dose due to dispensing fees on top of wholesale; Ro adds a prescriber-visit fee on top of drug acquisition cost.
- 2026-04-30DONE
FDA proposed 503B Bulks List exclusion for sema/tirz/lira
Separate from Foundayo but indirectly relevant: on April 30, 2026, the FDA proposed adding semaglutide, tirzepatide, and liraglutide to the 503B Bulks List exclusion, narrowing compounded-GLP-1 availability. This positions Foundayo at $149/month as the cheapest legal branded GLP-1 cash-pay path in the US, occupying the price tier compounded semaglutide and tirzepatide previously held.
- 2026-05-23DONE
Foundayo Savings Card terms fully published
Eli Lilly published the full Foundayo Savings Card terms at foundayo.lilly.com/coverage-savings: $25 copay if covered by commercial insurance, dose-tier non-covered self-pay at $149 (0.8 mg) / $199 (2.5 mg) / $299 (5.5 mg and up), $1,000/year cap, 10 fills/year, expires 12/31/2026. Government insurance excluded by federal anti-kickback statute (the BALANCE Model is the separate Medicare path).
- 2026-07-01ANNOUNCED
Medicare BALANCE Model goes live - $50/month for eligible Part D enrollees
Per Eli Lilly's announced terms, eligible Medicare Part D enrollees pay as low as $50/month for Foundayo starting July 1, 2026. Distinguishing feature: unlike Wegovy's ASCVD-only Medicare path, the Foundayo BALANCE Model does not appear to require documented cardiovascular disease - making it the most accessible Medicare GLP-1 path for obesity-only beneficiaries. Full implementation details still being published as launch approaches.
- 2026-08-31ANNOUNCED
Promotional pricing checkpoints (sema and tirz adjacent drugs)
Two related promotional dates fall in this window: (a) the Wegovy NovoCare $199 starter promo for 0.25 / 0.5 mg ends June 30, 2026 - moves to $349/month standard; (b) the NovoCare oral Wegovy 25 mg 4 mg promotional discount runs through August 31, 2026, then moves to $199/month. Foundayo pricing itself is not promotional - $149/$199/$299 dose tiers are the standard LillyDirect structure.
- Q3 2026EXPECTED
Major commercial insurer formulary cycle - expected formulary inclusion wave
Commercial insurers (Aetna, Cigna, UnitedHealthcare, Anthem BCBS) typically add new GLP-1s to formulary on quarterly review cycles. The Q2 2026 cycle was too tight after April 1 FDA approval; Q3 is the realistic first inclusion wave. Expect prior authorization requirements similar to Wegovy / Zepbound: documented BMI threshold, prior weight-loss attempts, sometimes provider counseling. Per /insurance pages for the latest carrier-by-carrier status.
- Q3-Q4 2026EXPECTED
Telehealth platform expansion - Hims & Hers, LifeMD, Lemonaid
Ro was a launch partner on April 9, 2026. Hims & Hers, LifeMD, and Lemonaid are expected to add Foundayo through Q2-Q4 2026 as their respective Lilly partnerships extend. Pricing on these platforms typically bundles a monthly prescriber-visit fee with drug cost.
- Late 2026EXPECTED
Real-world adherence and outcome data emerges
First quarter of post-launch real-world adherence data from LillyDirect and partner telehealth platforms will start surfacing in Lilly investor calls and quarterly earnings (Q3 2026 reporting). This is the first data point on whether oral-pill convenience translates to materially higher adherence versus the weekly injection alternatives.
Why this launch matters for GLP-1 cost dynamics
Foundayo's April 2026 launch is the first credible cost-side disruption since Zepbound's LillyDirect vial program. At $149/month for the lowest dose, it occupies the price tier that compounded semaglutide and tirzepatide held before the FDA closed those channels in 2025-2026. Combined with the announced $50/month Medicare BALANCE Model on July 1, Foundayo is positioned as the cheapest accessible GLP-1 path across the broadest set of patient situations - which puts price pressure on Wegovy ($349 NovoCare, $249 subscription) and Zepbound ($299-$449 LillyDirect) without requiring patent expiration or biosimilar approval. The 2031-2037 biosimilar window for sema and tirz is far enough out that competitive launches like Foundayo are the price mechanism for the rest of this decade.
Frequently asked questions
When can I get Foundayo right now?
Right now, today. Foundayo has been available via LillyDirect since April 6, 2026, and via retail pharmacies (CVS, Walgreens) and Ro telehealth since April 9. The cheapest cash-pay path is LillyDirect at $149/month for the 0.8 mg lowest dose. Higher doses up to $299/month within the 45-day refill window.
When will my insurance add Foundayo?
Likely Q3 2026 for most major commercial insurers (Aetna, Cigna, UnitedHealthcare, Anthem BCBS). Insurers typically run formulary updates on quarterly review cycles, and Foundayo only received FDA approval on April 1, 2026 - too late for the Q2 cycle in many cases. If your plan has not added Foundayo as of June 2026, expect to file a formulary exception or use LillyDirect cash-pay until your plan's next quarterly update.
When does the Medicare BALANCE Model start?
July 1, 2026, per Eli Lilly's announced terms. Eligible Part D enrollees pay $50/month - lower than the LillyDirect cash-pay floor, but contingent on your specific Part D plan adding Foundayo at the BALANCE Model tier. Many Part D plans will not have added Foundayo by July 1 because of the quarterly formulary cycle; expect broader Part D inclusion through Q3 2026. See /foundayo-medicare-balance-model for the full BALANCE Model breakdown.
Will Foundayo be on Medicaid?
Medicaid is state-by-state and not part of the BALANCE Model. As of June 2026, most state Medicaid programs have not added Foundayo to their preferred drug lists. Expect a long tail through 2026-2027 as state PDLs catch up. Some states (CA, NY, MA among others) move faster on newly-approved obesity drugs; others (TX, FL) typically wait 6-12 months post-approval. Check your state Medicaid agency's PDL for the latest.
When will the Foundayo Savings Card expire?
December 31, 2026, per the published terms at foundayo.lilly.com/coverage-savings. Lilly typically extends savings card terms annually before expiration, so a 2027 renewal is expected but not guaranteed. The card provides $25 copay if your commercial insurance covers Foundayo, or non-covered self-pay tiers at $149 / $199 / $299 by dose if it does not.
When will Foundayo get a generic?
Not soon. Orforglipron is a small molecule (non-peptide) GLP-1 receptor agonist, so the path after patent expiration is the traditional small-molecule generic pathway (Hatch-Waxman) rather than the slower biosimilar pathway that applies to semaglutide and tirzepatide. But Eli Lilly's composition-of-matter patents on orforglipron extend into the late 2030s. Realistic generic orforglipron timing in the US: 2038-2042 window. The earlier cost-pressure mechanism is competitive launches (CagriSema phase 3, retatrutide phase 3), not generics.
When will real-world adherence data on Foundayo become public?
Late 2026 to early 2027. Lilly typically reports adherence and persistence data in quarterly earnings calls; Q3 2026 (reporting in late October / early November) will be the first quarter with a meaningful post-launch usage window. This will be the first signal on whether daily-pill convenience drives materially higher adherence than weekly Zepbound injection.
How does this timeline compare to Zepbound's launch?
Zepbound was FDA-approved on November 8, 2023 and launched commercially in December 2023. LillyDirect Zepbound vials (the cash-pay program) launched in August 2024, about 9 months post-approval. Foundayo compressed this dramatically: LillyDirect started shipping 5 days after FDA approval (April 6 vs April 1), enabled by the $1.5B pre-manufactured supply under the CNPV review window. Zepbound's Medicare picture remains absent in 2026 because there is no Zepbound BALANCE Model equivalent; Foundayo is months ahead on the Medicare path.
Related guides
Track Foundayo (orforglipron) pricing and availability
Eli Lilly's daily oral pill Foundayo (orforglipron) was FDA-approved April 1, 2026 and starts at $149/mo via LillyDirect. We'll email you when pricing tiers change, insurance coverage expands, or new head-to-head data lands vs. Wegovy and Zepbound.